Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies.
animal models
atherosclerosis
cardiovascular disease
experimental methods
myocardial infarction
platelet activation
proprotein convertase subtilisin/kexin type 9
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
16
07
2022
revised:
31
07
2022
accepted:
04
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial factor in the development and progression of cardiovascular diseases. PCSK9 has been demonstrated to modify LDL plasma levels and increase platelet activation, which promotes atherosclerosis, a defining feature of nearly all cardiovascular diseases. Platelet activation has been shown to promote and maintain the response to atherosclerosis development, from beginning to progression and exacerbation, which can lead to advanced cardiovascular events including myocardial infarction (MI) or death. Research on PCSK9 and platelet activation is currently underway with the main goal of reducing the risk of advanced cardiovascular events by preventing or slowing down atherosclerosis progression. Both in vitro and in vivo studies have been used to explore PCSK9 functions to develop new drugs targeting PCSK9. Finding the most suitable study models that represent the pathological and physiological systems found in humans is very important to achieving the goal. This review aimed to present a current and comprehensive overview of the experimental models that have been used to investigate the role of PCSK9 in platelet activation-induced atherosclerotic cardiovascular diseases.
Identifiants
pubmed: 36005422
pii: jcdd9080258
doi: 10.3390/jcdd9080258
pmc: PMC9409389
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Universitas Indonesia
ID : Hibah PUTI RA 2022
Références
Pharmacol Ther. 2015 Feb;146:104-19
pubmed: 25277507
Front Physiol. 2020 Nov 12;11:602497
pubmed: 33262707
Trends Biochem Sci. 2007 Feb;32(2):71-7
pubmed: 17215125
Life (Basel). 2022 Jan 27;12(2):
pubmed: 35207479
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
Tex Heart Inst J. 2006;33(3):290-3
pubmed: 17041683
J Am Heart Assoc. 2018 Mar 23;7(6):
pubmed: 29572319
Hum Mol Genet. 2006 May 1;15(9):1551-8
pubmed: 16571601
J Am Coll Cardiol. 2018 Feb 27;71(8):952-954
pubmed: 29471945
Appl Biochem Biotechnol. 2018 Dec;186(4):805-815
pubmed: 29740798
Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):60-74
pubmed: 24062891
Int J Mol Sci. 2021 Oct 16;22(20):
pubmed: 34681838
Nature. 2021 May;593(7859):429-434
pubmed: 34012082
Sci Transl Med. 2013 Jan 2;5(166):166ra1
pubmed: 23283366
Biomed Pharmacother. 2019 Feb;110:456-464
pubmed: 30530048
Circ Res. 2014 Mar 14;114(6):1022-36
pubmed: 24625727
Shock. 2016 Dec;46(6):672-680
pubmed: 27405064
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):282-291
pubmed: 31653513
Mol Ther. 2021 Jun 2;29(6):2019-2029
pubmed: 33609733
Circulation. 2021 Jan 5;143(1):45-61
pubmed: 32988222
Circulation. 2012 Feb 21;125(7):894-901
pubmed: 22261195
J Lipid Res. 2018 Feb;59(2):207-223
pubmed: 29180444
J Biomed Res. 2015 Aug 20;30:
pubmed: 26585560
J Am Coll Cardiol. 2015 Apr 14;65(14):1454-71
pubmed: 25857912
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5
pubmed: 15118091
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):237-245
pubmed: 31236571
J Cell Mol Med. 2019 Nov;23(11):7310-7319
pubmed: 31557388
N Engl J Med. 2006 Mar 23;354(12):1264-72
pubmed: 16554528
Nat Biotechnol. 2018 Sep;36(8):717-725
pubmed: 29985478
Nat Genet. 2003 Jun;34(2):154-6
pubmed: 12730697
Mo Med. 2013 May-Jun;110(3):207-11
pubmed: 23829104
Transl Res. 2018 Feb;192:30-45
pubmed: 29175268
J Clin Invest. 2006 Nov;116(11):2995-3005
pubmed: 17080197
J Atheroscler Thromb. 2017 May 1;24(5):462-472
pubmed: 28302950
Hum Mutat. 2009 Apr;30(4):520-9
pubmed: 19191301
J Thromb Haemost. 2007 Jul;5 Suppl 1:203-11
pubmed: 17635728
J Biol Chem. 2004 Nov 19;279(47):48865-75
pubmed: 15358785
Metabolites. 2022 Jan 12;12(1):
pubmed: 35050192
Atherosclerosis. 2013 Apr;227(2):297-306
pubmed: 23422832
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20
pubmed: 18695239
J Lipid Res. 2012 Jan;53(1):51-65
pubmed: 22021650
Biol Pharm Bull. 2015;38(5):785-8
pubmed: 25947925
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Apr 25;50(2):229-238
pubmed: 34137224
Eur Heart J. 2016 Feb 7;37(6):554-60
pubmed: 26508163
Glob Cardiol Sci Pract. 2017 Mar 31;2017(1):e201702
pubmed: 28971102
BMC Cardiovasc Disord. 2014 Dec 17;14:192
pubmed: 25519174
Sci Rep. 2017 Oct 30;7(1):14360
pubmed: 29084995
Int J Cardiol. 2017 Jan 15;227:644-649
pubmed: 27810295
Antioxidants (Basel). 2020 Apr 02;9(4):
pubmed: 32252393